Your browser doesn't support javascript.
loading
Human adipose-derived stem cells genetically programmed to induce necroptosis for cancer immunotherapy.
Bak, Soyeon; Kim, Kyoung Sub; Na, Kun.
Afiliação
  • Bak S; Department of Biomedical-Chemical Engineering, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, 14662, Republic of Korea.
  • Kim KS; Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, 14662, Republic of Korea.
  • Na K; Department of Biomedical-Chemical Engineering, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, 14662, Republic of Korea.
Cancer Gene Ther ; 31(7): 995-1006, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38858535
ABSTRACT
Herein, we present human adipose-derived stem cells (ADSCs) inserted with the receptor-interacting protein kinase-3 (RIP3) gene (RP@ADSCs), which induces cell necroptosis, for tumor immunotherapy. Necroptosis has characteristics of both apoptosis, such as programmed cell death, and necrosis, such as swelling and plasma membrane rupture, during which damage-related molecular patterns are released, triggering an immune response. Therefore, necroptosis has the potential to be used as an effective anticancer immunotherapy. RP@ADSCs were programmed to necroptosis after a particular time after being injected in vivo, and various pro-inflammatory cytokines secreted during the stem cell death process stimulated the immune system, showing local and sustained anticancer effects. It was confirmed that RIP3 protein expression increased in ADSCs after RP transfection. RP@ADSCs continued to induce ADSCs death for 7 days, and various pro-inflammatory cytokines were secreted through ADSCs death. The efficacy of RP@ADSCs-mediated immunotherapy was evaluated in mouse models bearing GL-26 (glioblastoma) and K1735 (melanoma), and it was found that RP resulted in an increase in the population of long-term cytotoxic T cells and a decrease in the population of regulatory T cells. This shows that RP@ADSCs have potential and applicability as an excellent anticancer immunotherapy agent in clinical practice.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Necroptose / Imunoterapia Limite: Animals / Humans Idioma: En Revista: Cancer Gene Ther Assunto da revista: GENETICA MEDICA / NEOPLASIAS / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Necroptose / Imunoterapia Limite: Animals / Humans Idioma: En Revista: Cancer Gene Ther Assunto da revista: GENETICA MEDICA / NEOPLASIAS / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido